» Articles » PMID: 11896335

Posttransplant Immune-mediated Hemolysis

Overview
Journal Transfusion
Specialty Hematology
Date 2002 Mar 16
PMID 11896335
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Immune-mediated hemolysis is a well-recognized complication of transplantation, but few reports have drawn together the different mechanisms that could be involved.

Study Design And Methods: The clinical and laboratory records of three patients are used to illustrate different types and complexities of posttransplant immune-mediated RBC destruction.

Results: Patient 1 received bone marrow from an HLA-matched, unrelated donor. At 7 months after transplant, his Hb level fell to 50 g per L. The serum contained warm autoantibodies, and the DAT was strongly positive for IgG, IgM, and C3d; an eluate yielded IgG and IgM autoantibodies. Autoimmune hemolytic anemia was diagnosed. Patient 2, blood group A, experienced severe hemolysis 14 days after receiving a lung from a group O donor. The DAT was positive for IgG. Serum and RBC eluate contained anti-A produced by immunocompetent B cells in the transplanted lung-this was the passenger lymphocyte syndrome. Patient 3 experienced posttransplant hemolysis caused by two different immune mechanisms. Originally group A, D- with anti-C, -D, -E, she received a peripheral blood progenitor cell (PBPC) transplant from her HLA-identical group A, D+ son. Six months later, chimerism was evident; the remaining recipient marrow was still producing antibodies that destroyed D+ RBCs made by the transplant. Later, autoimmune hemolytic anemia also developed; the DAT became positive for IgG, and warm autoantibodies were eluted from D- RBCs.

Conclusion: An understanding of the causes and circumstances under which posttransplant immune hemolysis arises is required for proper management. As more patients become long-term survivors of unrelated bone marrow and/or PBPC transplants, chimerism and complex serologic problems will become more common.

Citing Articles

Impact of Blood Products Transfusion on Patients in the Immediate Post-Lung Transplant Period: A Cohort Study.

Siddiqui A, Shakil J Ann Transplant. 2024; 29:e943652.

PMID: 38590090 PMC: 11015745. DOI: 10.12659/AOT.943652.


Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation in adults: A southern China multicenter experience.

Lv W, Qu H, Wu M, Fan Z, Huang F, Xu N Cancer Med. 2019; 8(15):6549-6558.

PMID: 31502764 PMC: 6825994. DOI: 10.1002/cam4.2539.


IgA-mediated autoimmune haemolytic anaemia in a 9-year renal transplanted patient.

Ignace S, Villar E, Broussais F, Moncharmont P, Vial T, Pouteil-Noble C NDT Plus. 2019; 1(1):28-29.

PMID: 30792780 PMC: 6375234. DOI: 10.1093/ndtplus/sfm015.


Transfusion management and immunohematologic complications in liver transplantation: experience of a single institution.

Solves P, Carpio N, Moscardo F, Lancharro A, Cano I, Moya A Transfus Med Hemother. 2015; 42(1):8-14.

PMID: 25960710 PMC: 4404898. DOI: 10.1159/000370260.


Alemtuzumab plus cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel transplant.

Lauro A, Stanzani M, Finelli C, Zanfi C, Morelli M, Pasqualini E Case Rep Transplant. 2014; 2014:262953.

PMID: 25177510 PMC: 4142660. DOI: 10.1155/2014/262953.